Top

Cancer Cell International

Published in:

Open Access 01-12-2020 | Pancreatic Cancer | Primary research

Bioinformatics analysis combined with experiments to explore potential prognostic factors for pancreatic cancer

Authors: Mu-jing Ke, Lian-dong Ji, Yi-xiong Li

Published in: Cancer Cell International | Issue 1/2020

Abstract

Background

Pancreatic cancer is a common malignant tumor of the digestive tract. It has a high degree of malignancy and poor prognosis. Finding effective molecular markers has great significance for pancreatic cancer diagnosis and treatment. This study aimed to investigate DLGAP5 expression in pancreatic cancer and explore the possible mechanisms and clinical value of DLGAP5 in tumorigenesis and tumor development.

Methods

Differentially expressed genes were screened using the Gene Expression Omnibus (GEO) data set GSE16515. Gene Ontology (GO)-based functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis were performed on the corresponding proteins of the above genes using the Database for Annotation, Visualization, and Integrated Discovery (DAVID). The Kaplan–Meier Plotter database was used to analyze the relationship between differentially expressed genes and pancreatic cancer prognosis. The most prognostic gene, DLGAP5, was screened out, and the Oncomine and gene expression profiling interactive analysis (GEPIA) databases were used to analyze its expression in pancreatic cancer and other cancer tissues. The Cancer Genome Atlas (TCGA) database was used to analyze the overall survival of DLGAP5. Gene set enrichment analysis (GSEA) was performed to explore its possible molecular mechanisms in pancreatic cancer. Furthermore, the biological behavior of DLGAP5 in pancreatic cancer was verified by cell function experiments.

Results

A total of 201 significant upregulated differentially expressed genes and 79 downregulated genes were selected. The biological processes with significant enrichment of differential genes included cell adhesion, apoptosis, wound healing, leukocyte migration, angiogenesis. Pathways were mainly enriched in tumor-related signaling pathways such as cancer pathways, the extracellular matrix-receptor interaction pathway, and the p53 signaling pathway. DLGAP5 was significantly expressed in pancreatic cancer, and its expression level had a significant effect on patients’ survival time and progression-free survival. GSEA results indicated that DLGAP5 had significantly enriched into signaling pathways such as the cell cycle, the p53 signaling pathway, and oocyte meiosis. The experimental results showed that when we knocked down the expression of DLGAP5 in pancreatic cancer cells, their proliferation ability was significantly inhibited, and their invasion and migration ability significantly decreased.

Conclusions

DLGAP5 can be used as a prognostic indicator for pancreatic cancer and affect the occurrence and development of pancreatic cancer.

Available only for authorised users

Beeghly-Fadiel A, Luu HN, Du L, Shi C, McGavic DP, Parikh AA, Raskin L. Early onset pancreatic malignancies: clinical characteristics and survival associations. Int J Cancer. 2016;139:2169–77. https://doi.org/10.1002/ijc.30273.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. https://doi.org/10.3322/caac.21254).CrossRef

Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. https://doi.org/10.1016/s0140-6736(16)00141-0).CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442).CrossRefPubMed

Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T. Familial pancreatic cancer: concept, management and issues. World J Gastroenterol. 2017;23:935–48. https://doi.org/10.3748/wjg.v23.i6.935.CrossRefPubMedPubMedCentral

Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol. 2016;8:55–66. https://doi.org/10.4251/wjgo.v8.i1.55).CrossRefPubMedPubMedCentral

Duan L, Hu XQ, Feng DY, Lei SY, Hu GH. GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J Surg. 2013;36:7–12. https://doi.org/10.1016/j.asjsur.2012.08.001).CrossRefPubMed

Yi XP, Han T, Li YX, Long XY, Li WZ. Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway. Mol Med Rep. 2015;12:601–8. https://doi.org/10.3892/mmr.2015.3380).CrossRefPubMed

Shi S, Cao H. Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K/Akt signaling pathway. Oncol Lett. 2014;8:1087–9. https://doi.org/10.3892/ol.2014.2293.CrossRefPubMedPubMedCentral

10.

Yang Z, Li D, Liu Z, Miao X, Yang L, Zou Q, Yuan Y. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance. Cancer Biomark. 2016;17:437–44. https://doi.org/10.3233/cbm-160660.CrossRefPubMed

11.

Wang L, Xiong L, Wu Z, Miao X, Liu Z, Li D, Zou Q, Yang Z. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance. World J Surg Oncol. 2018;16:11. https://doi.org/10.1186/s12957-018-1316-7.CrossRefPubMedPubMedCentral

12.

Rasmussen AH, Rasmussen HB, Silahtaroglu A. The DLGAP family: neuronal expression, function and role in brain disorders. Mol Brain. 2017;10:43. https://doi.org/10.1186/s13041-017-0324-9).CrossRefPubMedPubMedCentral

13.

Kim E, Naisbitt S, Hsueh YP, Rao A, Rothschild A, Craig AM, Sheng M. GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J Cell Biol. 1997;136:669–78.CrossRef

14.

Naisbitt S, Kim E, Weinberg RJ, Rao A, Yang FC, Craig AM, Sheng M. Characterization of guanylate kinase-associated protein, a postsynaptic density protein at excitatory synapses that interacts directly with postsynaptic density-95/synapse-associated protein 90. J Neurosci. 1997;17:5687–96.CrossRef

15.

Wu H, Reissner C, Kuhlendahl S, Coblentz B, Reuver S, Kindler S, Gundelfinger ED, Garner CC. Intramolecular interactions regulate SAP97 binding to GKAP. EMBO J. 2000;19:5740–51. https://doi.org/10.1093/emboj/19.21.5740).CrossRefPubMedPubMedCentral

16.

Naisbitt S, Valtschanoff J, Allison DW, Sala C, Kim E, Craig AM, Weinberg RJ, Sheng M. Interaction of the postsynaptic density-95/guanylate kinase domain-associated protein complex with a light chain of myosin-V and dynein. J Neurosci. 2000;20:4524–34.CrossRef

17.

Santarella RA, Koffa MD, Tittmann P, Gross H, Hoenger A. HURP wraps microtubule ends with an additional tubulin sheet that has a novel conformation of tubulin. J Mol Biol. 2007;365:1587–95. https://doi.org/10.1016/j.jmb.2006.CrossRefPubMed

18.

Wong J, Fang G. HURP controls spindle dynamics to promote proper interkinetochore tension and efficient kinetochore capture. J Cell Biol. 2006;173:879–91. https://doi.org/10.1083/jcb.200511132).CrossRefPubMedPubMedCentral

19.

Shi YX, Yin JY, Shen Y, Zhang W, Zhou HH, Liu ZQ. Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Sci Rep. 2017;7:8072. https://doi.org/10.1038/s41598-017-08615-5).CrossRefPubMedPubMedCentral

20.

Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F, Meister M. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol. 2017;50:365–72. https://doi.org/10.3892/ijo.2017.3834.CrossRefPubMedPubMedCentral

21.

Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba): identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(S4):S11.CrossRef

22.

Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G. TumGrowth: an open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology. 2018;7(9):e1462431.CrossRef

23.

Liao W, Liu W, Yuan Q, Liu X, Ou Y, He S, Yuan S, Qin L, Chen Q, Nong K, Mei M, Huang J. Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS ONE. 2013;8:e80789. https://doi.org/10.1371/journal.pone.0080789).CrossRefPubMedPubMedCentral

24.

Horning AM, Wang Y, Lin CK, Louie AD, Jadhav RR, Hung CN, Wang CM, Lin CL, Kirma NB, Liss MA, Kumar AP, Sun L, Liu Z, Chao WT, Wang Q, Jin VX, Chen CL, Huang TH. Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell-cycle-related transcription and attenuated androgen response. Cancer Res. 2018;78:853–64. https://doi.org/10.1158/0008-5472.can-17-1924).CrossRefPubMed

25.

Hewit K, Sandilands E, Martinez RS, James D, Leung HY, Bryant DM, Shanks E, Markert EK. A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. Cell Death Dis. 2018;9:1069. https://doi.org/10.1038/s41419-018-1115-7).CrossRefPubMedPubMedCentral

26.

Chen X, Thiaville MM, Chen L, Stoeck A, Xuan J, Gao M, ShihIe M, Wang TL. Defining NOTCH3 target genes in ovarian cancer. Cancer Res. 2012;72:2294–303. https://doi.org/10.1158/0008-5472.can-11-2181).CrossRefPubMedPubMedCentral

27.

Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34. https://doi.org/10.1126/science.1075762.CrossRefPubMed

28.

Hanks SK, Hunter T, Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995;9:576–96.CrossRef

29.

Hunter T. Signaling–2000 and beyond. Cell. 2000;100:113–27.CrossRef

30.

Dixit A, Verkhivker GM. Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Comput Math Methods Med. 2014;2014:653487. https://doi.org/10.1155/2014/653487.CrossRefPubMedPubMedCentral

31.

Quan C, Xiao J, Liu L, Duan Q, Yuan P, Zhu F. Protein kinases as tumor biomarkers and therapeutic targets. Curr Pharm Des. 2017;23:4209–25. https://doi.org/10.2174/1381612823666170720113216.CrossRefPubMed

32.

Mc Gee MM. Targeting the mitotic catastrophe signaling pathway in cancer. Mediat Inflamm. 2015;2015:146282. https://doi.org/10.1155/2015/146282.CrossRef

33.

Cimini D. Merotelic kinetochore orientation, aneuploidy, and cancer. Biochem Biophys Acta. 2008;1786:32–40. https://doi.org/10.1016/j.bbcan.2008.05.003.CrossRefPubMed

34.

Pfau SJ, Amon A. Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep. 2012;13:515–27. https://doi.org/10.1038/embor.2012.65.CrossRefPubMedPubMedCentral

35.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRef

36.

Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226:352–64. https://doi.org/10.1002/path.3022).CrossRefPubMed

37.

Urrego D, Tomczak AP, Zahed F, Stuhmer W, Pardo LA. Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond. 2014;369:20130094. https://doi.org/10.1098/rstb.2013.0094).CrossRef

38.

Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harbor Persp Biol. 2010;2:a000893. https://doi.org/10.1101/cshperspect.a000893).CrossRef

39.

Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375–404. https://doi.org/10.1146/annurev-biochem-060815-014710).CrossRefPubMed

40.

Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25:304–17. https://doi.org/10.1016/j.ccr.2014.01.021).CrossRefPubMedPubMedCentral

Title: Bioinformatics analysis combined with experiments to explore potential prognostic factors for pancreatic cancer
Authors: Mu-jing Ke
Lian-dong Ji
Yi-xiong Li
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01474-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2

Podoplanin is indispensable for cell motility and platelet-induced epithelial-to-mesenchymal transition-related gene expression in esophagus squamous carcinoma TE11A cells

Promoter methylation, transcription, and retrotransposition of LINE-1 in colorectal adenomas and adenocarcinomas

Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p

Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis

LINC01089 is a tumor-suppressive lncRNA in gastric cancer and it regulates miR-27a-3p/TET1 axis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer